The American Conference Institute hosted a complimentary webinar titled “Pharma, Medical Device and Biotech Companies Discuss New Compliance Risks Amid Geopolitical Tensions” as part of its Life Sciences in China Series on Wednesday, March 19. The webinar addressed the new risk and compliance dilemmas confronting life sciences companies operating in China. The speakers, including Wilson Sonsini Litigation partner Tarek Helou, delved into the industry-specific issues at the forefront, the Trump administration’s priorities, and the next phase of legal and regulatory complexities and how to prepare. 

Topics included: 

• Navigating China’s new Healthcare Anti-Bribery Guidelines and crackdown
• Balancing compliance with China’s data and cyber laws with DOJ and SEC expectations for FCPA compliance
• Special considerations for onboarding and monitoring third parties in China, including distributors, sub-distributors, and agents
• Mitigating the risks associated with interactions with HCPs, device installation and maintenance, and clinical research